2018 Gastrointestinal Disorders Therapeutics Market to Reinvigorate the Market

Nov. 1, 2012 - PRLog -- Drugs to treat gastrointestinal disorders are due to see a significant price drop, as patents run out and research takes off, according to a new report by healthcare experts RnR Market Research.

The new report states that patients with disorders such as Irritable Bowel Syndrome (IBS), Crohns disease, Ulcerative Colitis (UC), Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD) will experience a rush in new generic versions of popular medication, and new novel drugs with the hope of better results.

The market for gastrointestinal disorder therapeutics is being driven by increased stress, unhealthy eating habits, the growth of the global elderly population and an increased level of awareness among the general population, which has spurred on the rise of incidence and diagnosis over the recent past. Anxiety, unhealthy foods and advanced age can all be associated with changes in gastrointestinal physiology. However, gastrointestinal diseases still have a low diagnosis rate, and a fear of serious side effects may restrain market growth.

The gastrointestinal disorders therapeutics market is set to experience strong generic competition during the forecast period, as several major branded drugs used in to treat gastrointestinal disorders are set to expire during 2011-2015, including Nexium (esomeprazole magnesium), Aciphex (rabeprazole sodium), Tysabri (natalizumab) and Humira (adalimumab). This will result in a decline in the Annual Cost of Treatment (ACT), from $291 in 2011 to $261 in 2018 at a negative Compound Annual Growth Rate (CAGR) of 1.5%, although the launch of novel biologics will stabilize this drop.

However the market is set to witness a steady growth from 2015 onwards due to the anticipated entry of innovative new drugs, as the industry shows strong R&D activity in IBS, constipation, Crohn’s disease and UC with effective and novel drug molecules. There are approximately 269 ongoing clinical trials in the gastrointestinal disorders therapeutics market, with the main focus being on Crohn’s disease and UC. 42% of all ongoing clinical trials are in Phase II and 22% are in the late stages (Phase III and NDA-filed). This robust pipeline increases the chance of getting new drugs to market and may represent better treatment options with fewer side effects.

The Irritable Bowel Syndrome (IBS) and constipation therapeutics markets were valued at $722m and $1.7 billion in 2011, and are expected to grow at CAGRs of 13.7% and 11.1% to $1.8 billion and $3.6 billion respectively in 2018. This high growth rate is attributed to the strong pipeline dominated by First-In-Class (FIC) molecules such as recently launched Linzess (linaclotide). Others include Plecanatide, Xifaxan (rifaximin), Asimadoline and Naloxegol (PEG-naloxol), most of which have demonstrated high safety and efficacy profiles in clinical trials. There is a significant level of unmet need associated with current treatment options for IBS and constipation, and if these new therapies can address them, they will be able to command a price premium, thus driving the market.

Buy Your Report Copy @ http://www.rnrmarketresearch.com/gastrointestinal-disorde...

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market
report provides in-depth analysis of the major gastrointestinal diseases, comprising IBS, constipation, Crohn’s disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). It gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and co-development deals that have taken place in the past two years.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by RnR Market Research team of industry experts.

Table of content of this report

1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12
2 Gastrointestinal Disorders Therapeutics Market - Introduction 15
2.1 Overview 15
3 Global Gastrointestinal Disorders Therapeutics Market - Market Characterization 16
3.1 Market Forecasts 16
3.1.1 Branded and Generic Global Market Share 18
3.1.2 Annual Cost of Treatment 19
3.1.3 Treatment Usage Patterns 20
3.2 Drivers and Restraints for the Global Gastrointestinal Disorders Therapeutics Market 22
3.2.1 Market Drivers 22
3.2.2 Market Restraints 23
4 Gastrointestinal Disorders Therapeutics Market - Geographical Landscape 24
4.1 Revenue Analysis by Geography 24
4.2 The US 24
4.2.1 Revenue 24
4.2.2 Annual Cost of Treatment 26
4.2.3 Treatment Usage Patterns 27
4.3 Top Five Countries of Europe 29
4.3.1 Revenue 29
4.3.2 Revenue by Country 30
4.3.3 Annual Cost of Treatment 32
4.3.4 Treatment Usage Patterns 33
4.4 Japan 35
4.4.1 Revenue 35
4.4.2 Annual Cost of Treatment 37
4.4.3 Treatment Usage Patterns 38
4.5 Gastrointestinal Disorders Therapeutics Market India-Overview 40
4.5.1 Epidemiology 40
4.5.2 Clinical Trials 41
4.5.3 Drivers and Restraints 41
4.6 Gastrointestinal Disorders Therapeutics Market Australia-Overview 42
4.6.1 Epidemiology 42
4.6.2 Clinical Trials 43
4.6.3 Drivers and Restraints 43
4.7 Gastrointestinal Disorders Therapeutics Market China-Overview 44
4.7.1 Epidemiology 44
4.7.2 Clinical Trials 45
4.7.3 Drivers and Restraints 45
5 Global Gastrointestinal Disorders Therapeutics Market - Therapeutic Landscape 46